

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6248211

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CONFIRMATORY ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AGNO PHARMA USA	07/10/2020
RECEIVING PARTY DATA	
Name:	NEUROCRINE BIOSCIENCES, INC.
Street Address:	12780 EL CAMINO REAL
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92130
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	15388960
Application Number:	16196234
Application Number:	16509552
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	+1 (212) 641-2323
Email:	apsi@fr.com
Correspondent Name:	ELIZABETH T. KARNAS
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	46696-0016001; 002; 003
NAME OF SUBMITTER:	SUZANNE C. O'NEILL
SIGNATURE:	/Suzanne C. O'Neill/
DATE SIGNED:	08/13/2020
Total Attachments: 5	
source=6. Confirmatory Assignment Agno to NBI 7-10-20#page1.tif	
source=6. Confirmatory Assignment Agno to NBI 7-10-20#page2.tif	
source=6. Confirmatory Assignment Agno to NBI 7-10-20#page3.tif	

source=6. Confirmatory Assignment Agno to NBI 7-10-20#page4.tif
source=6. Confirmatory Assignment Agno to NBI 7-10-20#page5.tif

CONFIRMATORY ASSIGNMENT

Assignor: Agno Pharma USA
a corporation organized and existing under the laws of Delaware, and having a place
of business at:
~~4500 New Brunswick Avenue~~ 752 56th Street, 1st Floor
~~Suite 102~~ New York, New York 11220 USA
~~Piscataway, NJ 08854~~
RAP 10 JUL 20

Assignee: Neurocrine Biosciences, Inc.
a corporation organized and existing under the laws of
Delaware, and having a place of business at:
12780 El Camino Real
San Diego, CA 92130

1. Assignor represents that it is the owner of the patents and patent applications on attached Schedule A, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns, and confirms any prior assignment, to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in its own name wherever so permitted by law or in the name of Assignee wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.
3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and

legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.

4. Assignor hereby assigns, and confirms any prior assignment, to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

The Assignor hereby acknowledges and accepts the foregoing assignment.

Assignor: Agno Pharma USA.

Signature: [Handwritten Signature]

Date: 10 JUL 20

Name: Raymond Dignone Jr

Title: SVP Business Development

Witnessed by:

Signature: [Handwritten Signature]

Date: 7/10/2020

Print Name: APRIL L. MUGLOWAN

Signature: [Handwritten Signature]


Date: 7/10/2020

Print Name: Brandy Thomas

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truth, legal, accuracy or validity of that document.

State of California, County of SAN DIEGO,
City of CHULA VISTA, before me, JAMES M. LEE, Notary Public,
personally appeared Raymond Dignone Jr
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are
subscribed to the within instrument and acknowledged to me that he/she/they executed the same in
his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the
person(s), or the entity upon behalf of which the person(s) acted, executed the instrument. I certify
under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraphs are
true and correct. WITNESS my hand and office seal.

[Handwritten Signature]



The Assignee hereby executes this Assignment.

Assignee: Neurocrine Biosciences, Inc.

Signature: David L. Bradfute

Date: 16 July 2020

Name: David L. Bradfute

Title: Vice President & Head, Intellectual Property

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California

County of San Diego

On July 16, 2020 before me, Lori A. Goldberg, Notary Public

(insert name and title of the officer)


personally appeared David L. Bradfute

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal

Signature Lori A. Goldberg



Schedule A

F&R Ref	Client Ref	Filed	Appln	Issue	Patent No.	Country
46696-0016001	035.US2.REG	12/23/2016	15/388,980	12/25/2018	10,160,757	UNITED STATES
46696-0016002	035.US3.CON	11/20/2018	16/196,234			UNITED STATES
46696-0016CA1	035.CA1.PCT	12/22/2016	3009169			CANADA
46696-0016CN1	035.CN1.PCT (MTPC)	12/22/2016	201680081331.X			CHINA
46696-0016EP1	035.EP1.PCT	12/22/2016	16823529.9			EUROPEAN PATENT CONVENTION
46696-0016HK1	035.HK1.EPO	12/22/2016	19122288.4			HONG KONG
46696-0016IN1	035.IN1.PCT	12/22/2016	201817023481			INDIA
46696-0016JP1	035.JP1.PCT (MTPC)	12/22/2016	2018-533230			JAPAN
46696-0016P01	035.US1.PRO	12/23/2015	62/387,442			UNITED STATES
46696-0016WO1	035.WO1	12/22/2016	PCT/US2016/068277			WIPO

23897391.doc